ICU Medical (NASDAQ:ICUI) Issues Quarterly Earnings Results

ICU Medical (NASDAQ:ICUI) released its earnings results on Thursday. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.30, FiscalAI reports. The firm had revenue of $556.22 million during the quarter, compared to analysts’ expectations of $552.03 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.03 earnings per share.

Here are the key takeaways from ICU Medical’s conference call:

• Q3 revenue was $556 million, up 5% organically, while adjusted EBITDA rose 8% to $114 million and adjusted EPS increased 20% to $2.44. Consumables and Infusion Systems each posted record sales.
• Management expects full-year adjusted EBITDA of $415 million–$435 million and adjusted EPS of $8.60–$9.00 to finish toward the high end of its existing ranges. Adjusted gross margin reached 42%, and the company reiterated its goal of reaching 43% by the end of 2027.
• Free cash flow was $83 million in Q3, supporting about $80 million of debt repayment and bringing net leverage to 2.0x. However, year-to-date cash flow benefited from tariff refunds and lower capital spending, and management expects Q4 free cash flow to be lower than Q3.
• Integration-related logistics problems disrupted international deliveries and weighed on Vital Care, which declined 10% organically in Q3; management expects a larger full-year decline for the segment. It said most of the operational issues should be resolved in Q4.
• ICU Medical reported progress on its product pipeline, including approvals for infusion pumps in Canada and Europe and plans to file a revised Medfusion 5000 syringe-pump application in the coming weeks. Several Consumables launches are planned for 2027, though the company said pump-install-base replacement is likely to unfold over 2027–2029.

ICU Medical Price Performance

ICU Medical stock traded up $4.46 during mid-day trading on Friday, reaching $172.11. The company had a trading volume of 464,850 shares, compared to its average volume of 283,141. The business has a fifty day simple moving average of $162.97 and a 200 day simple moving average of $149.18. The company has a market cap of $4.30 billion, a P/E ratio of 145.86, a P/E/G ratio of 2.17 and a beta of 0.88. ICU Medical has a fifty-two week low of $113.37 and a fifty-two week high of $192.85. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56.

Insider Activity at ICU Medical

In related news, insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the sale, the insider owned 3,076 shares of the company’s stock, valued at $548,512.32. This trade represents a 42.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Elisha W. Finney sold 378 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the sale, the director owned 4,871 shares in the company, valued at $888,860.08. This represents a 7.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 21,830 shares of company stock valued at $3,905,003. 2.10% of the stock is owned by company insiders.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

Wall Street Analyst Weigh In

ICUI has been the subject of a number of research analyst reports. Needham & Company LLC boosted their price target on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Piper Sandler lifted their target price on ICU Medical from $195.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, KeyCorp boosted their target price on ICU Medical from $187.00 to $189.00 and gave the stock an “overweight” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $195.20.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.